Navigation Links
Curemark Opens Patient Enrollment for Autism Treatment at Three More Clinical Trial Sites
Date:11/19/2009

RYE, N.Y., Nov. 19 /PRNewswire/ -- Curemark LLC, (www.curemark.com), a drug research and development company focused on the treatment of neurological diseases, announced that the company has begun enrolling patients in Phase III clinical trials for CM-AT, its autism treatment, at three additional clinical trial sites. The sites are the Southwest Autism and Resource Center in Phoenix, Arizona (SARRC); Pennsylvania State University's Pediatric Clinical Research Office at Hershey Medical Center in Hershey Pennsylvania; and the University of North Carolina at Chapel Hill.

Curemark is conducting Phase III clinical trials for CM-AT at 12 sites with a total 170 children across the country. The company previously announced that the first clinical trial patients were enrolled at Lake Mary Pediatrics in Orange City, Florida.

"We are extremely pleased with the progress of the Phase III trial enrollment for CM-AT and are continuing to move forward with the other sites in the study across the country," said Dr. Joan Fallon, Curemark founder and CEO. "Especially given the new data on the increased incidence of autism, we're excited to be this far along in our clinical program."

CM-AT is based on Fallon's breakthrough research that showed enzyme deficiencies in autistic children, resulting in an inability to digest protein. The inability to digest protein affects the production of amino acids, the building blocks of chemicals essential for brain function. CM-AT will be one of the first therapies to address the underlying physiology of autism, rather than just treat its symptoms.

A new study released in early October by the U.S. Centers for Disease Control (CDC) showed that the number of children affected by autism is much higher than originally thought. According to the CDC, autism affects 1 in 91 children and about 1 in 58 boys, totaling an estimated 673,000 or approximately 1% of all children in the U.S.

For information on participating in the CM-AT autism trials, log on to www.clinicaltrials.gov and search "Curemark."

About CUREMARK LLC

Curemark is a drug research and development company focused on the treatment of neurological and other diseases, especially those with dysautonomic components, by addressing certain key gastrointestinal/pancreatic secretory deficiencies. The company's initial products are based upon breakthrough observations by its founder, Dr. Joan Fallon, which revealed a lack of protein digestion in children with autism and ADHD. To learn more about our innovative science, visit www.curemark.com

Safe Harbor Statement

This news release contains forward-looking statements that involve risks and uncertainties that could cause our actual results and experiences to differ materially from anticipated results and expectations expressed in such forward-looking statement. These forward-looking statements include, without limitation, statements regarding the mechanism of action of CM-AT, its potential advantages, its potential for use in treating autism, as well as the timing, progress and anticipated results of the clinical development and regulatory processes concerning CM-AT. These statements are based on our current beliefs and expectations as to such future outcomes, and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a material difference include, among others, risks that the results of clinical trials will not support our claims or beliefs concerning the effectiveness of CM-AT, our ability to finance our development of CM-AT, regulatory risks, and our reliance on third party researchers and other collaborators. We assume no obligation to update these statements, except as required by law.

SOURCE Curemark LLC


'/>"/>
SOURCE Curemark LLC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Curemark Enrolls First Patients in Phase III Clinical Trials for Autism Treatment
2. Curemark Announces Senior Executive Promotions
3. Curemark CEO Presents at Epigenomics Conference
4. Curemark Closes Series A Financing
5. Curemark Appoints Preeminent Pediatrics Gastroenterologist
6. Diplomat Specialty Pharmacy Continues to Expand - Opens Location in Southern California
7. Eli Lilly and Company Opens Eco-Friendly Biotechnology Center on the West Coast Designed to Speed and Enhance Innovation
8. Center for Community Health Opens in Skid Row to Provide Healthcare Services to Nearly 9,000 Patients Annually
9. Whistleblowers Attorney Says Pfizers Guilty Plea Today Opens New Chapter on Aggressive Enforcement of Pharma Companies
10. TCP Innovations Opens First US Office
11. New Places and People - Truphatek opens USA subsidiary
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, Inc. ... will take whatever measures required to build a strong ... which is currently listed on the OTC Markets-pink current ... Chairman and CEO, "We are seeing an anomaly in ... understand, not only by the Company, but shareholders and ...
(Date:6/24/2016)... 2016  Consumers have taken a more active ... more emphasis on patient outcomes. ... the pharmaceutical industry have evolved beyond just providing ... are focusing on becoming more patient-oriented across their ... services that improve health. ...
(Date:6/24/2016)... FRANCISCO, Calif. , June 24, 2016 /PRNewswire/ ... ), a biopharmaceutical company developing novel therapeutics for ... unmet needs, today announced the closing of its ... of common stock, at the public offering price ... in the offering were offered by GBT. GBT ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether ... latter, setting the bar too high can result in disappointment, perhaps even self-loathing. However, ... their goal. , Research from PsychTests.com reveals that behind the tendency ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may suffer ... unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid ... healthy coping following a traumatic event. , Trauma sufferers tend to feel a range ...
(Date:6/24/2016)... ... ... Marcy was in a crisis. Her son James, eight, was out of control. Prone to ... , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there ... my other children and say he was going to kill them. If we were ...
(Date:6/24/2016)... ... 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida ... their peers for this recognition are considered among the top 2 percent of lawyers ... as members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... Comfort ... the American Cancer Society and the Road To Recovery® program to drive cancer patients ... seniors and other adults to ensure the highest quality of life and ongoing independence. ...
Breaking Medicine News(10 mins):